Baseline Characteristics of Study Population
| Parameter | Control group (n = 319) | Event group (n = 15) | P |
|---|---|---|---|
| Median age (y) | 59.0 (48.0, 66.0) | 66.0 (55.0, 71.5) | <0.05 |
| Men (n) | 123 (38.6%) | 10 (66.7%) | <0.05 |
| Body mass index | 25.2 ± 4.6 (15.0, 48.0) | 25.8 ± 5.6 (17.0, 35.0) | NS |
| Median follow-up time (mo) | 30.0 (20.0, 36.0) | 27.0 (21.0, 33.0) | NS |
| Events (n) | 15 | ||
| Cardiac | 10 | ||
| Cerebral | 5 | ||
| Cardiovascular risk factors (n) | |||
| Hypercholesterolemia | 57 (17.9%) | 3 (20%) | NS |
| Hypertension | 60 (18.8%) | 11 (73.3%) | <0.05 |
| Smoker | 30 (9.4%) | 4 (26.7%) | NS |
| Diabetes mellitus | 15 (4.7%) | 1 (6.7%) | NS |
| Family history of cardiovascular disease | 76 (25.2%) | 5 (33.3%) | NS |
| Mean calcified plaque sum | 4.6 ± 5.6 (0, 30) | 10.9 ± 8.3 (0, 23) | <0.05 |
| Mean TBR | 1.3 ± 0.2 (0.8, 2.0) | 1.9 ± 0.6 (1.4, 3.9) | <0.05 |
| Therapy (n) | |||
| Current statin medication | 14 (4.4%) | 1 (6.7%) | NS |
| Ongoing chemotherapy | 43 (13.5%) | 2 (13.3%) | NS |
NS = not statistically significant.
Values are mean ± SD followed by range, median followed by (Q1, Q3), or number followed by percentage.